根据年龄和性别的喘生物有效性在美国CHRONICLE研究中
Alan P Baptist1, Weily Soong2, Bradley E Chipps3
1Division of Allergy and Clinical Immunology, Henry Ford Health and Michigan State University, Detroit, Mich.
The journal of allergy and clinical immunology. Global
|December 1, 2025
概括
生物疗法有效地减少了严重喘的成年人的喘恶化. 现实世界的数据显示,在所有年龄组和两性之间都有一致的好处,支持广泛使用这些治疗方法.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的喘管理仍然具有挑战性.
- 生物疗法为严重喘提供了一个有希望的治疗途径.
- 患者人口统计学 (如年龄和性别) 对生物疗效的影响需要进一步研究.
研究的目的:
- 评估严重喘的成年人生物疗法在现实世界中的有效性.
- 分析按年龄和性别分层的治疗结果.
- 为了比较在开始生物治疗之前和之后的恶化率.
主要方法:
- 美国成年人患有严重喘的观察性研究 (CHRONICLE).
- 包括的患者患有无法控制的喘或需要全身皮质类固醇/免疫抑制剂.
- 比较喘恶化率6个月前后生物启动,没有先前的生物使用.
主要成果:
- 恶化率的减少因生物因素而异,但在所有年龄和性别群体中都得到了一致的观察.
- 具体减少范围从37%到63% (年龄在18-49岁),44%到52% (年龄在50-64岁) 和56%到63% (年龄在65岁以上).
- 男性的恶化率减少了34%至66%,女性的恶化率减少了46%至62%.
结论:
- 生物疗法有效地减少了严重喘的成年人喘恶化.
- 生物制剂的有效性在不同年龄组和性别之间是一致的.
- 研究结果支持在广泛的严重喘患者群体中使用生物疗法.
相关概念视频
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K


